Products may not be approved for sale as in vitro diagnostics in all countries.
Please contact us for further details.
Customers in the US, please contact MBL International Corporation for details. ⇒
|Anti-Synthetase ELISA Kit||7840R||96 wells||ELISA|
|MESACUP™ anti-MDA5 TEST||7874E||96 wells||ELISA|
|Anti-TIF1-γ ELISA Kit||7854R||96 wells||ELISA|
|Anti-Mi-2 ELISA Kit||7844R||96 wells||ELISA|
: Research Use Only Reagent
: CE-marked In vitro Diagnostic Reagent
Polymyositis and dermatomyositis (PM/DM) are systemic autoimmune disorders that involve muscle, skin and lungs. A number of autoantibodies are detected in PM/DM patient sera, some of which are specific to PM/DM (known as myostis-specific autoantibodies; MSAs) (1).
In addition to well characterized MSAs, such as anti-aminoacyl tRNA synthetase (ARS), anti-signal recognition particle, and anti-Mi-2 antibodies, a number of additional DM specific antibodies have been recently described. These include antibodies against melanoma differentiation-associated gene 5 (MDA5), transcriptional intermediary factor-1-gamma (TIF1-γ) (2).
- Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925-33.
- Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, et al. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PLoS One. 2016;11(4):e0154285.
Biomarker for Diagnosis and Prognosis of Dermatomyositis (DM) with Interstitial Lung Disease (ILD)
Ran Nakashima, MD, PhD
Rheumatology and Clinical Immunology, Kyoto University Hospital